Blog

Sunrise, FL – November 4, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce that it has received approval, effective today, from the Financial Industry Regulatory Authority (“FINRA”) to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of its Common Stock. In connection with the Company’s reverse stock split, FINRA has assigned the Company a new stock symbol, BHRTD. The Company’s stock will be quoted as BHRTD through December 2, 2015, and thereafter, the trading symbol will be USRM (OTC Markets), reflecting the new name of the Company. The new CUSIP number is 90350U100. Additional information on the above transaction and name change can be found in our November 4, 2015 Form 8-K filing. Current stock certificates may be exchanged for new certificates by contacting the Company’s transfer agent, Continental Stock Transfer & Trust Company at:

SUNRISE, FL / ACCESSWIRE / September 17, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (BHRT.OB)) – announces today that “insiders” led by Dr. William P. Murphy, Jr., Chairman and Mike Tomas, President and CEO, intend to purchase, in the open market, up to 5% of the issued and outstanding Common Stock of the Company. The planned insider purchases are subject to customary restrictions based upon any of the participant’s knowledge of material non-public information and are further subject to federal securities disclosure rules. As the planed insider purchases are to be executed by individuals, US STEM CELL cannot guarantee the number of shares to be purchased or the time frame in which these shares will be bought in the open market.

Sunrise, FL – March 19, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.

Sunrise, FL – March 17, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB),an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:

Sunrise, FL – January 29, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today the appointment of Martin E. Schmieg as President of Vetbiologics, Inc., the Company’s wholly owned animal health subsidiary.